Alexion Pharmaceuticals Inc. has postponed the filing of its third quarter earnings report with the US Securities and Exchange Commission (SEC) while an internal investigation is ongoing regarding sales of Soliris (eculizumab), apparently focusing on distribution to appropriate patients in the US.
The New Haven, Connecticut-based company disclosed its third quarter earnings to investors on Oct. 27, but missed a Nov. 9 deadline for submitting its Form 10-Q for the quarter to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?